Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy FDA Decision: Profound Medical (PRN)

The Phase 2 date for Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy by Profound Medical (PRN) is scheduled for May 1, 2026. This is the target date for the FDA to make a decision on this application.

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy is being developed by Profound Medical for the treatment of its target indication. It is currently in Phase 2 clinical trials.

If Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy receives FDA approval, Profound Medical (PRN) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 2 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for PRN on DilutionWatch at dilutionwatch.com/stock/PRN.html.

You can view the full BiotechSigns company profile for Profound Medical (PRN) at biotechsign.com/app/company/PRN, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.